Secukinumab reduce disfunción endotelial en pacientes con Psoriasis.

Journal Scan / Research · January 01, 2019

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients

Journal of Investigative Dermatology

TAKE-HOME MESSAGE

• This 52-week exploratory trial evaluated the effect of secukinumab on cardiovascular (CV) markers in patients with moderate to severe plaque psoriasis without clinical CV disease. Patients received secukinumab (300 mg or 150 mg) until week 52, or placebo until week 12 then secukinumab until week 52. Baseline endothelial function measured by flow-mediated dilation (FMD) was significantly lower in psoriasis patients than in healthy volunteers (4.4% vs 6.1%; P=.01). At week 12, the increase in the mean FMD was greater in patients treated with secukinumab compared with those treated with placebo, although it was not statistically significant. At week 52, FMD increased across all groups. FMD was significantly higher than at baseline in patients receiving secukinumab 300 mg for 52 weeks (+2.1%; P=.0022).

• This randomized controlled trial provides evidence that secukinumab may improve endothelial function in patients with psoriasis without clinical CV disease. Whether IL-17A inhibition leads to improved CV outcomes is yet to be determined.

– InYoung Kim, MD, PhD

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 2224-0654
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.